Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)

Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of lenalidomide was also not defined. This phase 2 study randomized 342 untreated patients with non-del(11q) CLL requiring therapy to...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Byrd, John C., Ruppert, Amy S., Heerema, Nyla A., Halvorson, Alese E., Hoke, Eva, Smith, Mitchell R., Godwin, John E., Couban, Stephen, Fehniger, Todd A., Thirman, Michael J., Tallman, Martin S., Appelbaum, Frederick R., Stone, Richard M., Robinson, Sue, Chang, Julie E., Mandrekar, Sumithra J., Larson, Richard A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2018
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058242/
https://ncbi.nlm.nih.gov/pubmed/30030269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015396
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia